Patent · US Active

Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine

US8871250B2 · kind B2 · utility

1Cited by
19References
28Claims
0Family size

Assignee

Inventor

Key dates

Filing dateJun 27, 2006
Grant dateOct 28, 2014
Priority date
Expiry dateFeb 22, 2030

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2333/4725
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1-based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.